Prof. Dror Harats, M.D. | Chief Executive Officer
Prof. Harats founded VBL in 2000 based on more than 20 years of both research in the field of medicine and biotechnology, as well as a strong background in management of early- to mid-stage biotechnology companies. He is also a professional and experienced consultant specializing in Biotechnology/Pharmaceutical healthcare companies. A professor of medicine in the department of internal medicine and the department of human molecular genetics and biochemistry at the Sackler Faculty of Medicine, Tel-Aviv University, Prof. Harats is the Chairman of the Bert Strassburger Lipid Center and the chairman of the IRB committee of the Sheba Medical Center, supervising about 2000 clinical trials annualy.
Prof. Harats received his M.D. from the Hadassah Medical School, the Hebrew University, Jerusalem, Israel. Following an Internship at Sheba Medical Center and a residency in Medicine at the Hadassah Medical Center in Jerusalem, he conducted a fellowship in pulmonary medicine and research in Molecular Genetics at The University of California in San Francisco (UCSF). He was then a Visiting Scientist at Syntex Discovery for three years. Prof. Harats published more than 180 peer-reviewed research papers and chapters in books, his publications rewarded him with numerous prizes and grants.
Erez Feige, Ph.D. , M.B.A. | Vice President, Business Operations
Dr. Feige joined VBL in 2006. He has extensive experience in cancer and immune-inflammatory research as well as in biochemistry, and molecular biology. Dr. Feige holds a Ph.D. and an M.B.A from Bar-Ilan University, Israel and completed a post-doctoral fellowship at the Dana-Farber Cancer Institute and Harvard Medical School in Boston, Mass., U.S.
Amos Ron | Chief Financial Officer
Mr. Ron joined VBL in 2011. Mr. Ron has more than 20 years experience at Israeli and multinational companies and has held CFO, COO, Site Director, Supply Chain Management and Product Marketing positions in the Bio-Pharm, Medical Device, CleanTech, Chemical and Textile industries. Mr. Ron holds an M.Sc. (Honors) in Chemical Technology Management from Hebrew University, Jerusalem, a B.Sc. in Business Administration, Empire State College (Jerusalem Branch) and a B.Sc. in Chemistry from Hebrew University.
Eyal Breitbart, Ph.D. | Vice President, Research & Operations
Dr. Breitbart joined VBL in 2001. He has extensive experience in both cancer and immune-inflammatory research as well as in biochemical, immunological and molecular biology methods and new product development. Dr. Breitbart holds a Ph.D. from Bar-Ilan University, Israel and completed a post-doctoral fellowship at Tufts University School of Medicine in Boston, Mass., U.S.
Yael Cohen, M.D. | Vice President, Clinical Development
Dr. Cohen joined VBL in 2008 and has been working in the pharmaceutical industry since 1999. Prior to joining VBL, she served as Vice President of Clinical Development in Gamida Cell Ltd, as the Medical Director of the Israeli subsidiary at Merck & Co., and then as a Clinical Scientist in Drug Development at Merck Research Labs in New Jersey. Dr. Cohen has extensive experience in both early- and late-stage clinical development and negotiations with regulatory agencies worldwide. Dr. Cohen holds an M.D. from the Sackler Medical School at Tel Aviv University and completed her residency in internal medicine at Sheba Medical Center in Israel, and a fellowship In Hematology at the Rabin medical Center. She is a senior physician at the Sourasky Medical Center hematooncology clinic.
Naamit Sher, Ph.D. | Vice President, Development and Regulatory
Dr. Sher Joined VBL in 2006. She was previously Head of QC Laboratories, Operations Division at Teva, and QC/QA Director at InterPharm, Subsidiary of Ares-Serono gaining 15 years of drug development and regulatory experience. Dr. Sher holds a Ph.D. from the Hebrew University, Israel and completed a post-doctoral fellowships at the Hebrew University, Jerusalem and at Rutgers University, New Jersey, U.S.
Corinne Epperly, M.D. , M.P.H. | U.S. Chief Operating Officer
Dr. Epperly joined VBL in 2017 and is an oncology expert with deep U.S. experience in drug development, strategy, commercialization and operations. Prior to joining VBL, she spent seven years at Bristol-Myers Squibb (BMS), where she delivered results across diverse roles spanning marketing, M&A, strategic operations and medical strategy in the U.S. Immuno-Oncology Business. Prior to joining BMS, she was a member of the Global Healthcare Investment Research team at Goldman Sachs, based in London. Dr. Epperly holds a dual graduate degree, an M.D. and Masters of Public Health from the University of North Carolina at Chapel Hill. She completed her medical training at the University of North Carolina Hospitals with the Department of Pediatrics. She also earned a Distinguished B.A. from the University of Virginia where she studied biochemistry and biology. Prior to medical school she conducted biomedical research in Experimental Immunology on checkpoint inhibition and tumor suppressor genes in the National Cancer Institute, National Institutes of Health.